Encysive TBC3711 On Clinical Hold

Encysive's next-generation selective endothelin receptor antagonist TBC3711 is subject to a clinical hold following an unexpected result in pre-clinical work

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet